Switch theme
Sign up to access all valuation multiples
Sanofi India Ltd is a drug manufacturing company that focuses on a range of therapeutic areas, including Diabetes, Cardiology, Consumer Healthcare, Hospital, Central Nervous System, and Anti-Histamines. The company's diabetes presence includes oral anti-diabetic products and insulin. The consumer healthcare area also maintains a nutraceutical portfolio. The company's export markets include Germany, the U.K., Australia, and Russia. The company utilizes strategic partnerships as a component of its growth.
1956
2.2K+
LTM Revenue $238M
LTM EBITDA $58.7M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sanofi India has a last 12-month revenue of $238M and a last 12-month EBITDA of $58.7M.
In the most recent fiscal year, Sanofi India achieved revenue of $234M and an EBITDA of $54.7M.
Sanofi India expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sanofi India valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $327M | $234M | XXX | XXX | XXX |
| Gross Profit | $172M | $181M | XXX | XXX | XXX |
| Gross Margin | 53% | 77% | XXX | XXX | XXX |
| EBITDA | $103M | $54.7M | XXX | XXX | XXX |
| EBITDA Margin | 31% | 23% | XXX | XXX | XXX |
| Net Profit | $72.1M | $70.0M | XXX | XXX | XXX |
| Net Margin | 22% | 30% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sanofi India's stock price is INR 6185 (or $72).
Sanofi India has current market cap of INR 142B (or $1.7B), and EV of INR 139B (or $1.6B).
See Sanofi India trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.7B | XXX | XXX | XXX | XXX | $1.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sanofi India has market cap of $1.7B and EV of $1.6B.
Sanofi India's trades at 6.8x LTM EV/Revenue multiple, and 27.5x LTM EBITDA.
Analysts estimate Sanofi India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sanofi India and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 6.9x | XXX | XXX | XXX |
| EV/EBITDA | 29.6x | XXX | XXX | XXX |
| P/E | 34.5x | XXX | XXX | XXX |
| P/E/Growth | 7.3x | XXX | XXX | XXX |
| EV/FCF | 32.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSanofi India's NTM/LTM revenue growth is 7%
Sanofi India's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $31K for the same period.
Over next 12 months, Sanofi India's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sanofi India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sanofi India and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -29% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -47% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 30% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $31K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 29% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sanofi India acquired XXX companies to date.
Last acquisition by Sanofi India was XXXXXXXX, XXXXX XXXXX XXXXXX . Sanofi India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sanofi India founded? | Sanofi India was founded in 1956. |
| Where is Sanofi India headquartered? | Sanofi India is headquartered in India. |
| How many employees does Sanofi India have? | As of today, Sanofi India has 2.2K+ employees. |
| Is Sanofi India publicy listed? | Yes, Sanofi India is a public company listed on BOM. |
| What is the stock symbol of Sanofi India? | Sanofi India trades under 500674 ticker. |
| When did Sanofi India go public? | Sanofi India went public in 1991. |
| Who are competitors of Sanofi India? | Similar companies to Sanofi India include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sanofi India? | Sanofi India's current market cap is $1.7B |
| What is the current revenue of Sanofi India? | Sanofi India's last 12-month revenue is $238M. |
| What is the current EBITDA of Sanofi India? | Sanofi India's last 12-month EBITDA is $58.7M. |
| What is the current EV/Revenue multiple of Sanofi India? | Current revenue multiple of Sanofi India is 6.8x. |
| What is the current EV/EBITDA multiple of Sanofi India? | Current EBITDA multiple of Sanofi India is 27.5x. |
| What is the current revenue growth of Sanofi India? | Sanofi India revenue growth between 2023 and 2024 was -29%. |
| Is Sanofi India profitable? | Yes, Sanofi India is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
